INTRODUCTION

Hepatic hydrothorax (HH) is a complication of advanced cirrhosis characterized by transudative pleural effusion in the absence of underlying cardiac or pulmonary disease, with an estimated rate of 5–10% in cirrhotic patients. HH results from pathologic trans-diaphragmatic migration of ascitic fluid in patients with liver cirrhosis. In one study, HH was right-sided in 70% of cases, left-sided in 18%, and bilateral in 12%. Patients with minimal pleural effusion may be asymptomatic or have pulmonary symptoms of dyspnea, cough, chest discomfort, hypoxemia, or respiratory failure. They are prone to recurrent bouts of spontaneous bacterial pleuritis with or without concurrent spontaneous bacterial peritonitis.
ents in HH; therefore, patients with HH have poor underlying liver function. The development of HH represents progression to decompensated cirrhosis and warrants prompt consideration for liver transplantation (LT).

Although LT is the optimal treatment modality for HH, it has poor accessibility due to donor organ shortage. Long-term management of HH using methods other than LT is challenging, due to the underlying poor liver function and lack of clinical trials supporting a satisfactory therapy. Medical therapy with diuretics, as well as a low-salt diet, repeated thoracentesis, pigtail drainage, transjugular intrahepatic portosystemic shunt (TIPS), and surgery have been reported for the management of HH. However, no large-scale studies have determined the optimal treatment modality, other than LT, for patients with HH. Therefore, this study aimed to identify the clinical characteristics and outcomes of cirrhotic patients with HH undergoing various modalities, such as medical treatment, repeated thoracentesis, pigtail drainage, and surgery.

MATERIALS AND METHODS

Patients
The inclusion criteria were age ≥18 years, diagnosis of liver cirrhosis, and refractory HH occurring between January 2013 and December 2017. Since surgery for HH has been available since 2013 at our center, we included all patients who were diagnosed with HH within the study period. HH was defined as large transudative pleural effusion (>500 mL) in a patient in whom other causes, such as heart failure, pneumonia, and malignancy, had been excluded. Data were collected from hospital records, and data on mortality and cause of death were obtained using the Statistics Korea microdata integrated service (https://mdis.kostat.go.kr). The institutional review board committee of Chonnam National University Hospital (CNUH-2018-132) approved the study protocol, and the requirement for informed consent was waived as patient data were de-identified.

Pleural fluid analysis
All patients underwent more than one thoracentesis, and all samples of pleural fluid obtained initially were examined. Routine pleural fluid and serum examinations included cell counts with differential counts, gram stains, cultures, pleural fluid pH, serum and fluid protein levels, albumin level, bilirubin level, and lactate dehydrogenase (LDH) level.

Transudate pleural fluid was defined as having either a pleural fluid/serum protein ratio ≤0.5, a pleural fluid/serum LDH ratio ≤0.6, or a pleural fluid LDH level less than two-thirds of the upper limit of normal for serum LDH. Serum-pleural fluid analysis gradient was defined as the difference in albumin levels between serum and pleural fluid.

Treatment modalities
Patient groups were defined using four different treatment modalities. Serial thoracentesis group included patients who had at least more than two therapeutic thoracentesis without other treatment modalities and were on continuous diuretics therapy. The median time interval between consecutive thoracenteses was calculated in this group.

Pigtail drainage group included patients who had a pigtail catheter inserted using Seldinger technique and were on continuous diuretic therapy. Pigtail catheter was maintained for continuous drainage of pleural effusion, and re-insertion/removal was performed according to clinical requirements. Usually, thoracentesis was routinely performed before pigtail drainage for evaluation and initial management of hydrothorax. However, in case of massive pleural effusion that may not be managed with thoracentesis, initial drainage was achieved with pigtail drainage. If clinically needed, especially when a patient re-suffered from dyspnea after pigtail drainage removal, additional thoracentesis was performed. Pleurodesis was not performed in pigtail drainage group.

LT group included patients who underwent LT due to advanced liver cirrhosis combined with HH. Surgery group included patients who underwent surgery for the management of HH. All patients in surgery group underwent video-assisted thoracoscopic surgery (VATS) for the detection and closure of diaphragmatic defects (Supplementary Fig. 1, only online) with concomitant pleurodesis. Pleurodesis was performed with Abnoba Viscum F (ABNOBA GmbH, Pforzheim, Germany) in eight patients, and Steritalc® (Novatech SA, La Ciotat, France) powder in two patients. A 24-Fr chest tube was maintained for 7–8 days and removed after confirmation of stable chest tube drainage volume. Diaphragmatic defect closure was performed using sutures and additional fibrin glue. Postoperative positive expiratory end pressure (5–10 cmH2O) in an intubated state was maintained for 1 day, and peritoneal drainage for 5 days. Surgery for HH was considered successful if the patient had no recurrence of ipsilateral pleural effusion, or if they did not exhibit symptoms requiring drainage in case of recurrence. Surgery for HH was considered to have failed if there was recurrence of pleural effusion requiring drainage. After discharge, plain chest radiographs were obtained every 2 or 3 months in outpatient clinics to check for recurrence.

Patients with refractory HH were recommended to undergo LT. Consultations at specific departments were arranged for detailed counselling.

Definition and management of refractory HH
HH was diagnosed using the following international criteria: 1) serum-to-pleural fluid albumin gradient >1.1; 2) pleural fluid total protein <2.5 g/dL or pleural fluid/serum total protein ratio <0.5; 3) pleural fluid/serum LDH ratio <0.6; and 4) polymorphonuclear cell count <250 cells/mm³. Refractory HH was defined as pleural effusion that 1) failed to respond to re-
striction of salt intake, the maximum dose of diuretic treatment (spironolactone at 400 mg/day and furosemide at 160 mg/day), and serial thoracentesis of more than two times; or 2) reappeared rapidly after therapeutic thoracentesis.

The number of needle punctures for drainage per person-years and the amount of drainage per day were analyzed. The occurrence rates of acute kidney injury (AKI) and hepatorenal syndrome (HRS) were recorded. AKI was defined as an increase in serum creatinine level of ≥0.3 mg/dL within 48 h, or an increase in serum creatinine to ≥1.5 times the baseline level. HRS was defined as occurrence of AKI in patients despite diuretic cessation and albumin infusion, and chronic or acute hepatic disease with advanced hepatic failure and without any other apparent cause for AKI.

**Ascites grading**

Grading of ascites amount was based on the quantitative criteria proposed by the International Ascites club. Grade 1 ascites is mild and can be detected only by imaging examination, such as ultrasonography. Grade 2 ascites is moderate and evidenced by moderate symmetrical distension of the abdomen, and is therefore readily detectable on physical examination. Grade 3 ascites is large with marked distension of the abdomen.

**Statistical analysis**

Data are expressed as mean±standard deviation, or median with range. Chi-squared test or Student’s t-test was used for univariate analyses, and logistic regression was used for multivariate analyses. Analysis of variance was used for multifactorial comparisons. Cumulative overall survival was calculated using Kaplan-Meier method and compared between groups using log-rank test. Variables with \( p < 0.05 \) in univariate analysis were entered into multivariate Cox regression analysis. In all analyses, \( p < 0.05 \) was considered statistically significant. All statistical analyses were conducted using Statistical Package for the Social Sciences for Windows version 20.0 (IBM Corp., Armonk, NY, USA).

**RESULTS**

**Baseline clinical characteristics of enrolled patients**

We identified 52 patients who were diagnosed with HH during the study period. With sodium restriction and use of diuretics, HH was controlled in 11 patients, whereas 41 patients had refractory HH and underwent four treatment modalities for management of HH (Fig. 1). Baseline characteristics of enrolled patients are shown in Table 1. Male sex was predominant (80.5%), and the mean age was 60.4 years. Alcohol consumption was the most common cause of liver cirrhosis (46.3%), followed by hepatitis B virus infection (31.7%). The mean Child-Turcotte-Pugh (CTP) score was 10.1, and CTP C class was the most common (70.7%). The mean Model for End Stage Liver Disease (MELD) score was 19.7. In total, 29.3% of patients had a previous history of hepatic encephalopathy (grade >2).

**Table 1. Baseline Characteristics of Enrolled Patients**

| Characteristics                  | Patients (n=41) |
|----------------------------------|----------------|
| Age (yr)                         | 60.37±12.0     |
| Male                             | 33 (80.5)      |
| BMI (kg/m²)                      | 22.99±3.22     |
| Etiology of liver cirrhosis      |                |
| Alcoholic/HBV/HCV/Others         | 19 (46.3)/13 (31.7)/4 (9.8)/7 (17.1) |
| CTP score                        | 10.12±0.23     |
| A/B/C                            | 0 (0)/12 (29.3)/29 (70.7) |
| MELD score                       | 19.71±5.38     |
| Pleural fluid                    |                |
| Right/Left/Both                  | 35 (85.4)/2 (4.9)/3 (7.3) |
| pH/Protein                       | 7.28±1.18/1.31±0.60 |
| LDH/Albumin/SPAG                 | 184.67±124.70/0.58±0.35/2.07±0.43 |
| Serum APRI score                 | 1.94±1.63      |
| Platelets (×10³/μL)              | 79.95±40.99    |
| Creatinine                       | 1.15±0.67      |
| Sodium                           | 135.54±4.88    |
| History of encephalopathy (>Gr 2)| 12 (29.3)      |
| Amount of ascites Gr 0/1/2/3     | 7 (17.1)/10 (24.4)/11 (26.8)/13 (31.7) |
| Follow-up duration (day)         | 455.20±471.93  |

BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; CTP, Child-Turcotte-Pugh; MELD, model for end-stage liver disease; LDH, lactate dehydrogenase; SPAG, serum-pleural fluid albumin gradient; APRI, aspartate aminotransferase to platelet ratio index; Gr, grade. Values are presented as mean±standard deviation or n (%) unless otherwise indicated.
Table 2. Clinical Characteristics and Outcomes of Patients Based on Treatment Modalities

|                        | Serial thoracentesis (n=11) | Pigtail drainage (n=16) | Surgery (n=10) | Liver transplantation (n=4) | p value |
|------------------------|-----------------------------|-------------------------|----------------|-----------------------------|---------|
| Cause of cirrhosis     |                             |                         |                |                             |         |
| Alcohol                | 4 (36.4)                    | 10 (62.5)               | 4 (40.0)       | 1 (25.0)                    | 0.618   |
| HBV                    | 4 (36.4)                    | 3 (18.8)                | 3 (30.0)       | 3 (75.0)                    |         |
| HCV                    | 2 (18.2)                    | 0 (0.0)                 | 0 (0.0)        | 0 (0.0)                     |         |
| Idiopathic             | 1 (9.0)                     | 3 (18.8)                | 3 (30.0)       | 0 (0.0)                     |         |
| HCC                    | 4 (36.4)                    | 3 (18.8)                | 2 (20.0)       | 0 (0.0)                     | 0.729   |
| Diuretics dose         |                             |                         |                |                             |         |
| Furosemide (mg/day)    | 72.0                        | 55.0                    | 57.8           | 90.0                        | 0.373   |
| Spironolactone (mg/day)| 175.0                       | 146.2                   | 125.0          | 133.3                       | 0.917   |
| Albumin (g/dL)         | 2.94                        | 2.60                    | 2.49           | 2.95                        | 0.462   |
| Total bilirubin (mg/dL)| 2.39                        | 4.04                    | 3.15           | 7.38                        | 0.024   |
| PT (INR)               | 1.45                        | 1.77                    | 1.64           | 2.01                        | 0.013   |
| CTP (median, range)    | 9.0 (8–12)                  | 11.0 (8–13)             | 10.5 (9–12)    | 10.5 (10–13)                | 0.063   |
| MELD (median, range)   | 17.0 (10–22)                | 21.5 (14–32)            | 18.0 (11–28)   | 22.0 (17–29)                | 0.017   |
| Survival duration (median, range) | 868.0 (49–1817) | 79.0 (15–1064)          | 179.0 (48–980) | 601.5 (428–1270)           | <0.001  |
| 12 months mortality (%)| 18.2                        | 87.5                    | 70.0           | 0.0                         | <0.001  |

HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; PT, prothrombin time; INR, international normalized ratio; CTP, Child-Turcotte-Pugh; MELD, model for end-stage liver disease.

Values are presented as median (range) or n (%) unless otherwise indicated.

Clinical characteristics and outcomes of patients based on treatment modalities

Patients were categorized based on the treatment modalities they received for the management of HH: diuretics with serial thoracentesis, pigtail drainage, surgery, and LT. Moreover, 11 (26.8%) patients received diuretics with serial thoracentesis, 16 (39.0%) patients underwent pigtail drainage, 10 (24.4%) patients underwent surgery, and four (9.8%) patients underwent LT. Disease etiology did not differ among groups (Table 1). The median value of interval in serial thoracentesis group was 19 (range, 5–244) days. Although no statistically significant difference was found (p=0.06), the lowest CTP score was observed in serial thoracentesis group, and the highest score was observed in pigtail drainage group. MELD score was the highest in LT group and the lowest in serial thoracentesis group (22.0 vs. 17.0, p=0.017). Although surgery group showed slightly lower MELD scores than pigtail drainage group (18.0 vs. 21.5), no statistically significant difference was found (p=0.091). Mortality significantly differed among groups (Table 2). Fig. 2 shows the comparison of survival rates among treatment modalities according to Kaplan-Meier analysis.

Clinical outcomes in pigtail drainage and surgery groups in refractory HH patients

Table 3 shows the comparison of clinical outcomes and adverse events between pigtail drainage group and surgery group in patients with refractory HH. Given the small number of patients included in both groups, there were only few statistically significant differences in the comparisons. We calculated the number of needle punctures per year for pleural fluid drain-
Management of Hepatic Hydrothorax

racentesis compared to pigtail drainage group (0.9 vs. 18.8), but associated with a slightly higher number of needle punctures for paracentesis (8.4 vs. 4.8). As shown in Table 3, the cause of death did not differ significantly between the two groups, and various adverse events occurred in both groups, but not life-threatening events. However, in surgery group, some interventions, such as prolonged hospital stay, were needed due to the additional use of antibiotics and surgery (e.g., herniorrhaphy). We assessed the cut-off values of CPT score which may indicate poorer prognosis in surgery group, and patients with a CTP score >10 points had poorer death-related outcomes (p=0.038). Among 10 patients who underwent surgery, no perioperative mortality occurred; and all patients were discharged from the hospital after 22.5 days (median, range 7–50). Although diaphragmatic defects were found by VATS in nine patients, the defect could not be located in one patient, and only pleurodesis was performed. Including this patient, two (20.0%) patients experienced HH recurrence. Eight (80.0%) patients had an increased volume of ascites; and among these patients, five were administered increased dose of diuretics. Of these five patients, two patients experienced HRS, which eventually led to death. However, there was no difference in mortality rates between the two groups.

### Analysis of factors related to survival

We assessed multiple factors related to survival. In univariate analysis, body mass index (BMI) <19 kg/m², refractory HH managed with pigtail drainage, CTP score >10, history of severe hepatic encephalopathy (grade >2), ascites >grade 1, and MELD score ≥16 were related to poor outcomes (Table 4). In multivariate analysis, BMI <19 kg/m², refractory HH managed with pigtail drainage, and CTP score >10 were related to poor survival rates with statistical significance.

### DISCUSSION

This study demonstrated the characteristics and clinical outcomes of patients treated with four different modalities for the management of HH. Some previous studies have reported on the results of various modalities for HH treatment; however, these studies were limited to a few methods. To the best of our knowledge, this is the first study to elucidate and compare the safety and efficacy of surgery and pigtail drainage, representing refractory HH patients with decompensated cirrhosis encountered in clinical practice.

Regarding risk factors for HH, alcohol consumption was the most common cause of HH in the present study. Chronic alcohol consumption has been reported to be the main cause of HH, and this was consistent with our results. The use of corticosteroids, diuretics, and nutritional support was common in our study, as these are standard treatments for HH. However, a recent study suggested that the use of diuretics may not be effective in reducing the amount of ascites and may lead to rebound ascites, requiring careful monitoring and adjustment of treatment strategies.

### Table 3. Comparison of Clinical Outcomes between Pigtail Drainage and Surgery Groups

|                         | Surgery (n=10) | Pigtail (n=16) | p value |
|-------------------------|---------------|---------------|---------|
| Number of needle punctures for drainage/year | 9.3           | 23.5          | 0.161   |
| Thoracentesis            | 0.9           | 18.8          | 0.016   |
| Paracentesis             | 8.4           | 4.8           | 0.381   |
| Thoracentesis            | 125.5         | 288.0         | 0.320   |
| Occurrence of AKI        | 5 (50.0)      | 11 (68.8)     | 0.548   |
| Occurrence of HRS        | 3 (30.0)      | 8 (50.0)      | 0.432   |
| Cumulative overall survival (day) | 402.1         | 221.7         | 0.113   |
| Cut-off value of CTP     | >10           | -             | 0.038   |
| Cause of death           | 6             | 14            |         |
| Hepatic failure          | 2 (33.3)      | 6 (42.9)      |         |
| HRS                     | 2 (33.3)      | 4 (28.6)      |         |
| Varice bleeding          | 1 (16.7)      | 1 (7.1)       |         |
| HCC progression          | 1 (16.7)      | 2 (14.3)      |         |
| Sepsis                   | -             | 1 (7.1)       |         |
| Adverse events           |               |               |         |
| Chest tube site oozing   | 1             | Pigtail site oozing 7 |         |
| Delayed port site bleeding |            | Pigtail site infection 1 |         |
| Incisional hernia        | 1             | Pigtail site pain* 4 |         |
| Pneumonia                |               |               |         |
| Urinary tract infection  |               |               |         |
| CRBI                     |               |               |         |
| Perioperative mortality  | 0             |               |         |
| Recurrence of HH         |               |               |         |

AKI, acute kidney injury; HRS, hepatorenal syndrome; CTP, Child-Turcotte-Pugh; HRS, hepatorenal syndrome; HCC, hepatocellular carcinoma; CRBI, central catheter-related bacterial infection; HH, hepatic hydrothorax.

Values are presented as n (%) unless otherwise indicated.

*Defined as pain that required intervention.
Table 4: Univariate and Multivariate Analyses on Survival Rates

| Factors                          | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | HR (95% CI)         | p value               | HR (95% CI)         | p value               |
| BMI <19 (kg/m²)                 | 6.6 (1.81–24.92)    | 0.001                 | 15.5 (3.23–74.58)   | 0.001                 |
| Serial thoracentesis            | 0.41 (0.17–0.99)    | 0.053                 |                       |                       |
| Pigtail drainage                | 4.24 (1.97–9.14)    | <0.001                | 4.52 (2.02–10.15)    | <0.001                |
| Surgery                         | 1.24 (0.50–3.08)    | 0.639                 |                       |                       |
| LT                              | 0.03 (0.00–1.93)    | 0.103                 |                       |                       |
| CTP score >10                   | 3.6 (1.81–7.32)     | <0.001                | 2.9 (1.22–7.14)      | 0.021                 |
| History of severe encephalopathy| 2.7 (1.33–5.44)     | 0.004                 |                       |                       |
| Ascites >Gr 1                   | 2.2 (1.01–4.62)     | 0.038                 |                       |                       |
| MELD ≥16                        | 2.6 (1.12–5.93)     | 0.033                 |                       |                       |

HR, hazard ratio; CI, confidence interval; BMI, body mass index; LT, liver transplantation; CTP, Child-Turcotte-Pugh; Gr, grade; MELD, model for end stage liver disease.

cohoh consumption and poor calorie intake causes muscle atrophy, resulting in low BMI and cachexia. These factors may increase the risk of anatomic thinning and the separation of collagenous fibers in the tendinous portion of the diaphragm.

Regarding treatment modality other than LT, many management options are available, such as serial thoracentesis, pigtail drainage, chest tube insertion, TIPS, and surgery. However, most patients have severely decompensated liver cirrhosis with poor liver function. Therefore, many difficulties are associated with making treatment decisions in clinical practice.

In terms of clinical outcomes based on treatment modalities, LT had the most favorable outcomes. Although the total number of patients who underwent LT was small, all four patients survived, with median survival duration of 601.5 days. Consistent with other studies, patients who underwent serial thoracentesis showed better survival than those who underwent pigtail drainage or surgery in our study. Unlike other studies that did not consider the liver function of patients in each group, serial thoracentesis group had better liver function than the other two groups (pigtail drainage and surgery) in the current study. This better liver function, rather than treatment modality, might have led to the higher survival rate. Therefore, considering the impracticality of LT in clinical practice, serial thoracentesis on demand can be an option for patients with relatively preserved liver function. However, serial thoracentesis was not effective in some patients with more advanced cirrhosis; and in these cases, pigtail drainage or surgery was performed in the present study.

Traditionally, surgery for HH is considered to have high risks for morbidity and mortality due to portal hypertension and poor liver function. Although there have been several studies concerning the surgical management of HH, these studies are limited and clinical outcomes were not positive. However, the results of the present study showed a success rate of 80.0% without recurrence and surgery-related mortality. Furthermore, compared to pigtail drainage, needle puncture was required less frequently, and the total drainage amount of pleural and peritoneal fluid was smaller (9.3 times vs. 23.5 times, 125.5 mL/day vs. 288 mL/day, respectively). However, paracentesis was required more frequently in surgery group as per the main mechanism of HH (the passage of ascites via diaphragmatic defects), and the distribution of ascitic fluid between peritoneal and thoracic cavities became confined to peritoneal cavity only, increasing the occurrence rate of ascites. For these reasons, the obliteration of diaphragmatic defects can eventually increase the amount of ascitic fluid. However, despite evaluating the dose of diuretics, AKI and HRS occurred more frequently in pigtail drainage group than in surgery group, although statistically not significant (p=0.548, p=0.432, respectively). Kaplan-Meier analysis revealed that the cumulative overall survival was longer in surgery group than in pigtail drainage group (402.1 days vs. 221.7 days, p=0.113). However, this superior result of surgery group may be due to selection bias that patients in surgery group may have had more preserved liver function and better performance score than those in pigtail drainage group. Although it was not statistically significant, both CPT score and MELD score was lower in surgery group.

Furthermore, we compared survival rates between patients with CTP scores >10 and those with CTP scores ≤10. CTP >10 group had poorer survival rate than CTP ≤10 group. This suggests that in patients who are ineligible for LT, considering its ability to provide better quality of life and non-inferior survival duration compared to pigtail drainage, surgery can be an option in patients with refractory HH and CTP ≤10. No significant difference in the causes of death was found between the two groups. Although no life-threatening events occurred, various adverse events, such as chest tube site oozing, bleeding, hernia due to increased peritoneal pressure, infections, and pain, occurred in both groups.

TIPS is recommended in several studies and guidelines for managing HH, and the following criteria for TIPS have been suggested: age <65 years, MELD <18, CTP class A or B, cardiac ejection fraction >60%, no history of severe encephalopathy, no response to diuretic treatment, and/or repetitive therapeutic thoracentesis. However, these criteria in refractory
HH patients have a narrow spectrum due to poor liver function, and their application in practice is challenging. The patients enrolled in this study had a median MELD score of 19, and 70.7% of patients had CTP class C. Furthermore, 29.3% of patients had a history of severe hepatic encephalopathy (grade 2). For these reasons, TIPS was not considered a treatment modality in most cases of refractory HH in the present study.

In multivariate analysis for survival, BMI <19 kg/m², HH managed with pigtail drainage, and CTP score >10 were associated with poor survival rate. Patients with liver cirrhosis exhibit progressive loss of fat and muscle mass. Severe loss of muscle and body mass are known to be related to poor prognosis. In this study, cachexia with low BMI (<19 kg/m²) was the strongest factor associated with survival rate (hazard ratio 10.6, p=0.002). Therefore, encouraging cirrhosis patients with low BMI to gain body weight and providing them with nutritional intervention should be considered in clinical practice. CTP score, which reflects the grade of ascites and encephalopathy, was related to survival rates, rather than MELD score.

This study had several limitations. First, this was a single-center retrospective study based on hospital records and loco-regional patient information. Second, the number of included patients was small, due to the short survival duration of decompensated liver cirrhosis patients and low incidence rate of HH. Considering the small sample size and selection bias, which may have occurred when deciding the treatment modality for various patient conditions, these factors may have influenced the clinical outcomes of treatment modalities and may be impetuous to draw a conclusion. Therefore, further studies investigating a large number of patients with hydrothorax are required.

In conclusion, serial thoracentesis may be recommended for management of HH. In patients who have refractory HH not managed with serial thoracentesis, surgical management can be a useful option, alternative to pigtail drainage despite several concerns. Further studies investigating a large number of patients with hydrothorax are required.

ACKNOWLEDGEMENTS

This study was supported by grants (CRI 18091-1) from Chonnam National University Hospital Biomedical Research Institute.

AUTHOR CONTRIBUTIONS

Conceptualization: Sung Kyu Choi and Yochun Jung. Data curation: Jae Hyun Yoon and Hee Joon Kim. Formal analysis: Jae Hyun Yoon. Funding acquisition: Jae Hyun Yoon and Chung Hwan Jun. Investigation: Jae Hyun Yoon and Chung Hwan Jun. Methodology: Jae Hyun Yoon. Project administration: Chung Hwan Jun and Sung Kyu Choi. Resources: Chung Hwan Jun and Yochun Jung. Software: Hee Joon Kim and Sung Bum Cho. Supervision: Sung Kyu Choi and Yochun Jung. Validation: Yochun Jung and Sung Bum Cho. Visualization: Sung Bum Cho. Writing—original draft: Jae Hyun Yoon and Hee Joon Kim. Writing—review & editing: Jae Hyun Yoon and Chung Hwan Jun.

REFERENCES

1. Malagari K, Nikita A, Alexopoulos E, Broontzos E, Papathanasiou M, Mitromaras J, et al. Cirrhosis-related intrathoracic disease. Imaging features in 1038 patients. Hepatogastroenterology 2005;52: 558-62.
2. Foschi FG, Piscaglia F, Pompilli M, Corbelli C, Marano G, Righini R, et al. Real-time contrast-enhanced ultrasound—a new simple tool for detection of peritoneal-pleural communications in hepatic hydrothorax. Ultraschall Med 2008;29:538-42.
3. Rubinstein D, McNlnes E, Dudley FJ. Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management. Gastroenterology 1985;88(1 Pt 1):188-91.
4. Xirol X, Tremosa G, Castellote J, Gornals J, Lama C, Lopez C, et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int 2005;18:672-5.
5. Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med 1999; 107:262-7.
6. The Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: ascites and related complications. Clin Mol Hepatol 2018;24:230-77.
7. Machicau VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology 2014;59:1627-37.
8. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38: 258-66.
9. Hsu SL, Tseng CW. Comparison of treatment of hepatic hydrothorax with catheter drainage versus serial thoracentesis. Curr Opin Pulm Med 2018;24:392-7.
10. Badillo R, Rockey DC. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore) 2014;93:135-42.
11. Hung TH, Tseng CW, Tsai CC, Hsieh YH, Tseng KC, Tsai CC. Mortality following catheter drainage versus thoracentesis in cirrhotic patients with pleural effusion. Dig Dis Sci 2017;62:1080-5.
12. Peters TJ, Martin F, Ward K. Chronic alcoholic skeletal myopathy—common and reversible. Alcohol 1985;2:485-9.
13. Porcel JM. Management of refractory hepatic hydrothorax. Curr Opin Pulm Med 2014;20:352-7.
14. Mouroux J, Perrin C, Venissac N, Blaive B, Richelme H. Management of pleural effusion of cirrhotic origin. Chest 1996;109:1093-6.
15. Milanez de Campos JR, Andrade Filho LO, de Campos Werebe E, Pandoulo FL, Filomeno LT, Jatene FB. Hepatic hydrothorax. Semin Respir Crit Care Med 2001;22:665-74.
16. Milanez de Campos JR, Filho LO, de Campos Werebe E, Sette H Jr, Fernandez A, Filomeno LT, et al. Thoracoscopic and talc poudrage in the management of hepatic hydrothorax. Chest 2000;118:13-7.
17. Nakamura Y, Iwazaki M, Yasui N, Seki H, Matsumoto H, Masuda R, et al. Diaphragmatic repair of hepatic hydrothorax with VATS after abdominal insufflation with CO(2). Asian J Endosc Surg 2012; 5:141-4.
18. Luh SP, Chen CY. Video-assisted thoracoscopic surgery (VATS) for the treatment of hepatic hydrothorax: report of twelve cases. J Zhejiang Univ Sci B 2009;10:547-51.
19. Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis 1997; 17:227-32.
20. Alberts WM, Salem AJ, Solomon DA, Boyce G. Hepatic hydrothorax. Cause and management. Arch Intern Med 1991;151:2383-8.
21. Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004;20:271-9.
22. Emerson PA, Davies JH. Hydrothorax complicating ascites. Lancet 1955;268:487-8.
23. Bhattacharya A, Mittal BR, Biswas T, Dhiman RK, Singh B, Jindal SK, et al. Radioisotope scintigraphy in the diagnosis of hepatic hydrothorax. J Gastroenterol Hepatol 2001;16:317-21.
24. Alonso JC. Pleural effusion in liver disease. Semin Respir Crit Care Med 2010;31:698-705.
25. Degawa M, Hamasaki K, Yano K, Nakao K, Kato Y, Sakamoto I, et al. Refractory hepatic hydrothorax treated with transjugular intra-hepatic portosystemic shunt. J Gastroenterol 1999;34:128-31.
26. Al-Zoubi RK, Abu Ghanimeh M, Gohar A, Salzman GA, Yousef O. Hepatic hydrothorax: clinical review and update on consensus guidelines. Hosp Pract (1995) 2016;44:213-23.
27. Plauth M, Schütz ET. Cachexia in liver cirrhosis. Int J Cardiol 2002; 85:83-7.